Cargando…
Expression of Msx-1 is suppressed in bisphosphonate associated osteonecrosis related jaw tissue-etiopathology considerations respecting jaw developmental biology-related unique features
BACKGROUND: Bone-destructive disease treatments include bisphosphonates and antibodies against the osteoclast differentiator, RANKL (aRANKL); however, osteonecrosis of the jaw (ONJ) is a frequent side-effect. Current models fail to explain the restriction of bisphosphonate (BP)-related and denosumab...
Autores principales: | Wehrhan, Falk, Hyckel, Peter, Ries, Jutta, Stockmann, Phillip, Nkenke, Emeka, Schlegel, Karl A, Neukam, Friedrich W, Amann, Kerstin |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2973937/ https://www.ncbi.nlm.nih.gov/pubmed/20942943 http://dx.doi.org/10.1186/1479-5876-8-96 |
Ejemplares similares
-
Bisphosphonate-associated osteonecrosis of the jaw is linked to suppressed TGFβ1-signaling and increased Galectin-3 expression: A histological study on biopsies
por: Wehrhan, Falk, et al.
Publicado: (2011) -
Increased human defensine levels hint at an inflammatory etiology of bisphosphonate-associated osteonecrosis of the jaw: An immunohistological study
por: Stockmann, Philipp, et al.
Publicado: (2011) -
Osteonecrosis of the jaw in a Crohn’s disease patient following a course of Bisphosphonate and Adalimumab therapy: a case report
por: Preidl, Raimund HM, et al.
Publicado: (2014) -
Osteoclast profile of medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis
por: Gross, Christian, et al.
Publicado: (2017) -
Osteoclastic expression of higher-level regulators NFATc1 and BCL6 in medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis
por: Wehrhan, Falk, et al.
Publicado: (2019)